Genentech's rheumatoid arthritis biologic gains FDA approval

01/10/2010 | San Francisco Chronicle

The FDA approved Genentech's Actemra, the only rheumatoid arthritis drug that targets the interleukin-6 protein, which plays a role in joint inflammation. The treatment is expected to benefit patients who do not respond to Remicade, Humira or Enbrel, which target an inflammatory protein called tumor necrosis factor-alpha.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC